longevity.
Epitalon is the most-studied peptide for telomere-targeted longevity research — a synthetic tetrapeptide shown to reactivate telomerase in human somatic cells in vitro. No peptide on PEPTIDEX has demonstrated human lifespan extension in a clinical trial. This page covers four peptides targeting four distinct hallmarks of cellular aging, with explicit evidence boundaries for each.
The Longevity stack.
A balanced protocol engineered for longevity via targeted peptide synergy.
4 peptides, precisely sequenced.
Each peptide plays a specific role. Removing any one breaks the synergy.
Customize this protocol
Open this protocol in the Cycle Planner to adjust duration, swap peptides, and generate your reference dosing chart.
Based on published trial data.
The Four Hallmarks of Cellular Aging: A Peptide Protocol for Each Layer
Biological aging is not a single process but a convergence of distinct cellular failure modes that accumulate in parallel over decades. The longevity peptide framework on this page targets four specific hallmarks: telomere attrition (the progressive shortening of chromosomal end-caps that limits cell division capacity), epigenetic dysregulation (the loss of gene expression fidelity as methylation patterns drift with age), mitochondrial dysfunction (the decline in bioenergetic efficiency that underlies age-related fatigue, cognitive decline, and metabolic deterioration), and circadian/metabolic desynchronization (the disruption of the AMPK/mTOR sensing axes that govern cellular energy allocation). Each tier addresses a distinct mechanism with its own evidence base and distinct limitations.
TIER 1 — Epitalon: Telomerase Reactivation and Telomere Elongation
Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Russian Academy of Medical Sciences. The primary mechanism is telomerase reactivation: Epitalon induces expression of the catalytic subunit of telomerase (hTERT) in telomerase-negative cells, restoring enzymatic activity and producing measurable telomere elongation. The Khavinson group published foundational in vitro evidence in two PubMed-indexed papers in the Bulletin of Experimental Biology and Medicine. The 2003 paper (PMID: 12937682) demonstrated Epitalon inducing hTERT expression, restoring telomerase activity, and producing telomere elongation in telomerase-negative human fetal fibroblasts. The 2004 paper (PMID: 15455129) demonstrated that Epitalon-treated human somatic cells exceeded the Hayflick limit by 10 additional divisions. Evidence boundary: both studies are in vitro human cell culture work. They demonstrate a real, reproducible telomere mechanism at the cellular level. They do not establish that systemic Epitalon in living humans produces equivalent in vivo telomere elongation or extends lifespan. Russian animal longevity data from the Khavinson program uses passive attribution: Research conducted at the St. Petersburg Institute of Bioregulation and Gerontology suggests Epitalon extended mean lifespan in animal models.
TIER 2 — GHK-Cu: Epigenetic Gene Regulation Against Aging
GHK-Cu (Glycine-Histidine-Lysine-Copper) is a naturally occurring tripeptide-copper complex found in human plasma at declining concentrations with age: approximately 200 ng/mL at age 20, falling to approximately 80 ng/mL by age 60. This age-related decline provides the biological rationale for the longevity application. Pickart et al. (2018, Int J Mol Sci; PMID: 29986520) analyzed GHK-Cu gene regulatory activity, finding it modulated expression of more than 4,000 human genes, reset aggressive cancer gene expression toward normal phenotypes, and reversed COPD-damaged lung gene expression patterns. The mechanisms span multiple transcription factor pathways including TGF-beta, Wnt, and NF-kB networks. The gene regulation scope is unusually broad for a simple tripeptide. Evidence boundary: primarily in vitro and tissue model data; no human RCT for aging-specific GHK-Cu endpoints exists. The declining plasma levels with age and the gene expression normalization data support a coherent biological hypothesis for longevity relevance without clinical confirmation.
TIER 3 — SS-31 (Elamipretide): Mitochondrial Cristae Remodeling
SS-31 (D-Arg-Dmt-Lys-Phe-NH2; pharmaceutical name Elamipretide) is a synthetic tetrapeptide that specifically accumulates in the inner mitochondrial membrane at cardiolipin-rich cristae, stabilizing cristae morphology and improving electron transport chain efficiency. Aging mitochondria develop aberrant cristae morphology, decreased complex I-IV activity, increased reactive oxygen species, and reduced ATP production. SS-31 directly addresses cristae remodeling. SS-31 has the strongest human evidence on this page: a 2017 randomized, placebo-controlled trial in Circulation: Heart Failure (PMID: 29217757) evaluated elamipretide in heart failure with reduced ejection fraction. The mechanism is directly applicable to the longevity context because cardiac aging is a mitochondrial aging process: cardiomyocyte cristae remodeling produces heart failure via the same mitochondrial architecture failure mode that reduces cellular energy capacity across aging tissues generally. Evidence boundary: the human RCT is in a cardiac disease population, not a healthy aging population. The clinical trial established SS-31 efficacy in pathological mitochondrial dysfunction; whether equivalent benefit exists in non-pathological aging remains an open question without completed human trials.
TIER 4 — MOTS-c: Mitochondrial-Derived Peptide for Metabolic Aging
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino acid peptide encoded in the mitochondrial genome making it one of the few known peptides of mitochondrial rather than nuclear genomic origin. MOTS-c is a retrograde signal from the mitochondria to the nucleus and cytoplasm, communicating mitochondrial metabolic status. Its primary mechanism is AMPK activation and modulation of the AMPK/mTOR axis, the core cellular energy sensing system whose dysregulation drives metabolic aging. The founding paper (PMID: 25738459, Lee et al. 2015, Cell Metabolism) identified MOTS-c as a mitochondrial peptide promoting metabolic homeostasis and reducing obesity and insulin resistance in animal models through AMPK-dependent regulation. A 2023 review in J Transl Med (PMID: 36670507) documented MOTS-c effects across stress, metabolism, and aging, identifying additional anti-inflammatory and skeletal muscle preservation mechanisms. Evidence boundary: MOTS-c human evidence is limited. The cellular biology is established, the clinical application for longevity remains preclinical. It is included because the mechanism (mitochondrial retrograde signaling via AMPK activation) is genuinely distinct from SS-31 (inner membrane architecture) and addresses the metabolic desynchronization dimension of aging that the other three peptides do not specifically target.
Research Evidence for Longevity Peptides
The longevity evidence landscape has a critical characteristic differentiating it from every other page on this platform: the primary endpoint (extended human lifespan, prevention of age-related disease) cannot be directly tested in short-duration clinical trials. All evidence cited here is mechanistic rather than outcomes-based. Explicit framing of what the evidence does and does not show is more important on this page than on any other.
Epitalon: In Vitro Human Cell Evidence
Khavinson et al. (2003, PMID: 12937682) conducted the foundational Epitalon telomerase study in human fetal fibroblasts - telomerase-negative cells that do not normally express the enzyme. Epitalon addition induced hTERT mRNA expression, restored telomerase enzymatic activity, and produced quantifiable telomere elongation. The 2004 follow-up (PMID: 15455129) demonstrated that treated cells exceeded the Hayflick limit by 10 additional divisions with maintained chromosomal integrity. These are in vitro findings in isolated cell cultures: reproducible, mechanistically significant, and not directly translatable to in vivo systemic aging. The Khavinson research program includes animal longevity studies in fruit flies and mice showing lifespan extension; these are Russian-language literature cited using passive attribution: Research conducted at the St. Petersburg Institute of Bioregulation and Gerontology suggests Epitalon extended mean lifespan in animal models.
GHK-Cu: Gene Regulation at Population Scale
The Pickart 2018 review (PMID: 29986520) analyzed GHK-Cu influence across publicly available gene expression databases, identifying modulation of over 4,000 genes. The most striking finding was the reset of aggressive cancer gene expression patterns toward normal phenotypes. GHK-Cu modulated pathways include: ubiquitin-proteasome system (protein quality control), anti-inflammatory networks (NF-kB downregulation), and tissue remodeling systems (MMP regulation). The declining plasma GHK-Cu concentration with age (200 ng/mL at age 20 vs. 80 ng/mL at 60) provides the biological rationale for supplementation. This gene regulatory profile supports longevity hypothesis plausibility without providing clinical efficacy evidence for aging outcomes in humans.
SS-31: The Only Human RCT on This Page
The elamipretide Circ Heart Fail paper (PMID: 29217757) provides the only human randomized controlled trial data on this page. The 2017 study demonstrated elamipretide improving left ventricular function and 6-minute walk distance in heart failure patients versus placebo. The mechanism of action - cardiolipin stabilization at the inner mitochondrial membrane, cristae morphology preservation, improved complex I-V electron transfer efficiency - is the direct mitochondrial aging mechanism. The clinical trial established that SS-31 produces measurable effects on mitochondrial function outcomes in a human population with pathological mitochondrial dysfunction. Whether equivalent benefit exists in non-pathological aging remains an open question without completed human trials in healthy aging populations.
MOTS-c: Founding Cell Metab Paper and 2023 Mechanistic Synthesis
Lee et al. 2015 (PMID: 25738459) established MOTS-c as a mitochondrially-encoded peptide that regulates nuclear gene expression and AMPK activity in metabolic tissues, with animal model evidence for anti-obesity and insulin-sensitizing effects. The 2023 J Transl Med review (PMID: 36670507) synthesized subsequent research, documenting additional mechanisms in aging tissues including reduction of senescence markers, anti-inflammatory activity, and muscle preservation. MOTS-c circulates at declining concentrations with age in humans; whether exogenous supplementation restores circulating levels to physiological effect is not established by published human trials.
Evidence Boundary Statement
No compound on this page has demonstrated extension of human healthy lifespan in a clinical trial. The evidence grades from SS-31 (highest: human RCT in disease population) through Epitalon (in vitro human cell evidence) and GHK-Cu (gene expression data) to MOTS-c (animal model and mechanistic review). All four are mechanistically plausible longevity research targets; none is clinically validated for the longevity endpoint. Any content claiming otherwise applies a lower editorial standard than this page maintains.
Tracking Longevity Protocol Outcomes
Longevity endpoints cannot be tracked directly in any practical timeframe. The metrics below capture upstream biomarkers most closely associated with the mechanisms each peptide targets.
- Epigenetic Clock (TruAge, Biological Insights) - Baseline and Annual: DNA methylation-based biological age tests measure epigenetic aging directly relevant to GHK-Cu and Epitalon mechanisms. Baseline before protocol; annual measurement tracks direction. A protocol showing slowed epigenetic clock progression provides evidence of mechanism engagement, not confirmed longevity benefit.
- Telomere Length Testing - Baseline and Annual: Commercial telomere length testing (LifeLength, TeloYears) maps directly to the Epitalon telomere mechanism. High intraindividual variability means single measurements are less informative than trends over years. Normal annual attrition is approximately 20-50 base pairs per year; attrition rate slowing or stabilization would be consistent with Epitalon mechanism engagement.
- VO2max and Lactate Threshold - Annual: Maximum oxygen uptake directly reflects mitochondrial oxidative phosphorylation capacity in skeletal muscle - the same bioenergetic parameter SS-31 and MOTS-c target. VO2max declines approximately 1% per year after age 30 in untrained individuals. Annual VO2max testing tracks trajectory. SS-31 and MOTS-c mechanism engagement would be expected to slow the VO2max decline rate.
- HOMA-IR (Insulin Sensitivity) - Every 6 Months: MOTS-c AMPK activation improves insulin sensitivity. HOMA-IR (fasting glucose x fasting insulin / 405) provides the most accessible insulin sensitivity proxy. Target: below 1.5 (optimal); above 2.5 indicates significant insulin resistance. HOMA-IR improvement over a MOTS-c protocol is the closest available biomarker to mechanism confirmation.
- Inflammatory Panel (hs-CRP, IL-6) - Every 6 Months: Chronic low-grade inflammation (inflammaging) is a convergent driver across all four longevity mechanisms. GHK-Cu NF-kB downregulation, SS-31 mitochondrial ROS reduction, and MOTS-c anti-inflammatory activity all target inflammaging from different angles. Baseline hs-CRP below 1 mg/L is optimal. Trajectories trending lower over the protocol provide systemic evidence of anti-inflammatory engagement across all four mechanisms, though hs-CRP is not specific to any one compound.
Alternative Approaches to Longevity
The longevity alternatives section is the most important on this platform to frame honestly. The longevity space is uniquely susceptible to overclaiming because the primary outcome cannot be verified in practical timeframes. Every longevity intervention claims mechanistic plausibility; very few have human evidence for the actual longevity endpoint.
The Highest-Evidence Non-Pharmacological Longevity Interventions
The interventions with the strongest human evidence for extended healthy lifespan are not peptides or pharmaceuticals but behavioral: (1) Aerobic exercise, specifically HIIT and zone 2 endurance - the only interventions with consistent human evidence for VO2max preservation, mitochondrial biogenesis, and AMPK activation, the same pathways MOTS-c and SS-31 target pharmacologically; (2) Caloric restriction or time-restricted eating, the most consistently replicated longevity intervention across species with human data on metabolic biomarkers; (3) Sleep quality (7-9 hours with adequate slow-wave sleep), the primary period of amyloid clearance, cellular repair, and autophagy activation; (4) Resistance training maintaining muscle mass, where sarcopenia prevention is the most consistent functional longevity predictor in epidemiological literature. Any longevity peptide protocol should be built on top of these foundations, not substituted for them.
Rapamycin (mTOR Inhibitor): The Most Evidence-Dense Longevity Pharmaceutical
Rapamycin is the most extensively studied pharmacological longevity intervention, extending lifespan in yeast, worms, flies, and mice with strong mechanistic consistency (mTOR pathway inhibition). In humans, rapamycin has FDA-approved use as an immunosuppressant and has entered investigational longevity use in clinics offering off-label pulsed dosing. The mechanism - mTOR inhibition promoting autophagy and reducing senescence-promoting anabolic signaling - is directly complementary to MOTS-c AMPK activation (AMPK and mTOR are opposing regulatory axes). Honest framing: rapamycin has the strongest pharmacological longevity evidence base, but its immunosuppressive mechanism creates real clinical risk for infectious disease requiring medical supervision. Not a self-directed supplement.
NAD Precursors (NMN, NR): Sirtuin Axis Support
Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) support NAD biosynthesis, which declines with age. NAD is essential for sirtuin activity (the epigenetic deacetylases linked to caloric restriction longevity effects) and PARP-mediated DNA repair. Several small human trials have demonstrated NMN/NR increasing blood NAD levels; downstream functional benefits in aging populations are more modestly supported. NMN and NR are among the most commercially available longevity supplements. They are in this alternatives section because MOTS-c addresses the same AMPK axis with a more specific mitochondrial-origin mechanism, and the functional longevity evidence for NAD precursors in humans remains preliminary relative to the commercial claims surrounding them.
Metformin: AMPK Activation with 70-Year Safety Record
Metformin, the most widely prescribed diabetes drug globally, activates AMPK through Complex I inhibition in liver mitochondria - the same AMPK axis that MOTS-c activates via mitochondrial retrograde signaling. The TAME (Targeting Aging with Metformin) trial is formally testing metformin as an anti-aging intervention in non-diabetic elderly populations. Metformin has a 70-year clinical safety record uniquely strong among any pharmacological longevity candidate. Its mechanism overlaps directly with MOTS-c; its evidence base exceeds MOTS-c substantially. Metformin belongs in alternatives rather than the primary protocol because it requires a prescription in most jurisdictions, and the TAME trial results are pending.
Senolytic Agents (Dasatinib + Quercetin): Clearing Senescent Cells
Senolytics selectively eliminate senescent cells, the zombie cells accumulating with age that secrete pro-inflammatory SASP factors degrading surrounding tissue. Dasatinib plus quercetin is the most studied senolytic combination in human pilot studies. This mechanism is distinct from the four longevity peptides on this page (which support mitochondrial function, telomere biology, and gene regulation rather than senescent cell clearance) and represents a complementary approach to a different aging hallmark. Dasatinib is a potent oncology drug: medical supervision required.
- Khavinson VKh et al. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. PubMed
- Khavinson VKh et al. (2004). Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. PubMed
- Pickart L et al. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. PubMed
- Gibson CM et al. (2017). Novel Mitochondria-Targeting Peptide Elamipretide in Heart Failure: A Randomized, Placebo-Controlled Trial. Circ Heart Fail. PubMed
- Lee C et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. PubMed
- Reynes B et al. (2023). Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. J Transl Med. PubMed
Estimated total cost for the Longevity stack (4 compounds) across verified vendors.
Totals are estimates — individual products must be added at vendor checkout. Affiliate links · Rankings independent.
Frequently asked questions.
Do any of these peptides actually extend human lifespan?
No published human clinical trial has demonstrated that any of the four peptides on this page extends human lifespan. Epitalon has in vitro evidence for telomerase reactivation in human somatic cells (PMIDs 12937682, 15455129) and Russian animal model data for lifespan extension, neither of which is human lifespan evidence. GHK-Cu has gene regulatory evidence in cell and tissue models. SS-31 has a human RCT in heart failure patients (PMID 29217757) showing mitochondrial functional improvement in a disease population, not healthy aging extension. MOTS-c has animal metabolic evidence. The honest statement: compelling mechanistic evidence exists across four distinct aging mechanisms; no human longevity outcome data exists for any of them.
What is Epitalon and why does it target telomeres?
Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology from the pineal gland peptide Epithalamin. Telomeres are the repetitive DNA end-caps on chromosomes that shorten with each cell division, ultimately triggering replicative senescence when critically short. Telomerase maintains telomere length in germ cells and stem cells but is silenced in most somatic cells. Khavinson et al. demonstrated Epitalon reactivates telomerase in normal human somatic cells that do not naturally express it (PMID: 12937682), producing measurable elongation. The 2004 paper (PMID: 15455129) showed treated cells exceeded the Hayflick limit by 10 additional divisions. This is in vitro human cell evidence, not confirmed by human in vivo longevity data. → Read more at peptidex.app/library/epitalon
Why does GHK-Cu decline with age and why does that matter?
GHK-Cu (Glycine-Histidine-Lysine complexed with copper) is a natural human plasma constituent present at approximately 200 ng/mL at age 20 and declining to approximately 80 ng/mL by age 60. This decline is well-documented; its functional consequence for aging is the subject of ongoing research. GHK-Cu was found to modulate expression of more than 4,000 human genes (PMID: 29986520), resetting aging and disease-associated gene expression patterns toward healthier phenotypes. The biological plausibility argument: a compound that declines with age, that has broad gene-regulatory activity consistent with anti-aging mechanisms, and that was originally identified in wound healing contexts represents a reasonable longevity research target. Clinical validation of this hypothesis is incomplete.
What is SS-31 and how does it differ from other mitochondrial supplements?
SS-31 (Elamipretide, D-Arg-Dmt-Lys-Phe-NH2) is a cell-permeable tetrapeptide that specifically concentrates in the inner mitochondrial membrane at cardiolipin-rich cristae. Most mitochondrial supplements (CoQ10, NAC, MitoQ) are small molecules that reach mitochondria but do not specifically target the inner membrane architecture. SS-31 targets cristae specifically - the folded inner membrane structures where electron transport chain complexes are organized. Age-related mitochondrial dysfunction is substantially driven by cristae flattening and disorganization. SS-31 stabilizes cristae morphology directly. The elamipretide RCT (PMID: 29217757) is the human evidence that this mechanism produces functional outcomes in a population with documented mitochondrial dysfunction.
What is MOTS-c and what makes it different from other peptides on this platform?
MOTS-c is unique on this platform: it is encoded in the mitochondrial genome rather than the nuclear genome. It is a retrograde messenger from the mitochondria to the nucleus and cytoplasm, communicating mitochondrial metabolic status. Its AMPK activation mechanism functions as an energy sensor signal: when mitochondrial function is suboptimal, MOTS-c activates AMPK to shift cellular priorities toward repair, autophagy, and fat oxidation over anabolic growth. MOTS-c circulating levels decline with age, one of the few longevity biomarkers that is mitochondrially encoded. Exogenous MOTS-c in animal models restores metabolic homeostasis and reduces age-related metabolic dysfunction (PMID: 25738459). → Read more at peptidex.app/library/mots-c
Can all four longevity peptides be combined in one protocol?
Yes - the four tiers address distinct mechanisms without pharmacological overlap: Epitalon targets nuclear telomere biology; GHK-Cu modulates epigenetic gene regulation; SS-31 stabilizes inner mitochondrial membrane architecture; MOTS-c activates AMPK retrograde mitochondrial signaling. No competitive interaction is documented. The combined protocol covers the full hallmarks-of-aging framework. That said, combining four research peptides simultaneously makes it impossible to attribute any observed effect to a specific compound. For mechanistic confirmation, sequential single-compound introduction with biomarker tracking provides better attribution data than simultaneous protocol launch.
What is the evidence quality difference between these four peptides?
Descending order of human evidence strength: (1) SS-31: human RCT in disease population (PMID: 29217757, Circ Heart Fail); (2) Epitalon: human somatic cell in vitro evidence for telomerase reactivation (PMIDs 12937682, 15455129) plus Russian animal longevity data (passive attribution); (3) GHK-Cu: broad gene expression regulation data from human cell and tissue databases (PMID: 29986520); (4) MOTS-c: animal metabolic evidence (PMID: 25738459) plus 2023 mechanistic review (PMID: 36670507), no human RCT. All four are research-only compounds for longevity applications.
How does this protocol compare to rapamycin?
Rapamycin (mTOR inhibitor) has the strongest cross-species pharmacological longevity evidence base: consistent lifespan extension in multiple animal models and the TAME trial testing it formally in humans. The mechanism (mTOR inhibition promoting autophagy) is complementary to MOTS-c AMPK activation - AMPK and mTOR are opposing regulatory axes. The key practical difference: rapamycin is an immunosuppressant at therapeutic doses, creating real infection risk requiring medical supervision and prescription. The peptides on this page have more favorable safety profiles for research use, substantially less human efficacy evidence, and different mechanistic targets. Rapamycin is the highest-evidence single pharmacological longevity intervention available to longevity clinics today.
Should I test biological age before starting a longevity protocol?
Yes - baseline biological age testing before any longevity protocol is strongly recommended. Epigenetic clock tests (TruAge, Biological Insights) provide a DNA methylation-based biological age estimate. If your biological age significantly exceeds chronological age, it identifies active epigenetic drift that GHK-Cu and Epitalon mechanisms directly address. If your biological age is below chronological age, the baseline establishes proof of existing positive trajectory to maintain. Annual retesting tracks protocol effect direction. Telomere length testing provides the second dimension relevant to Epitalon mechanism. Without baselines, any mid-protocol test has no interpretive context.
What is the appropriate mindset for a longevity peptide protocol?
Longevity peptide research is pre-clinical in terms of the primary endpoint (human lifespan extension). The appropriate framing is: (1) mechanistic plausibility is established for each compound at the cellular level; (2) the behavioral longevity foundations (exercise, sleep, diet, caloric restriction) have stronger human outcome evidence than any peptide and should be optimized first; (3) biomarker tracking (epigenetic clock, telomere length, VO2max, HOMA-IR, inflammatory markers) provides the most honest available window into protocol effects; (4) the longevity space is uniquely susceptible to wishful thinking - applying the same skeptical standard to your own protocol effects that you would apply to a commercial claim is the appropriate epistemics. This is an evidence-informed exploration of a promising but pre-clinical domain.
Is there a discount on research-grade longevity peptides like Epitalon and GHK-Cu?
Yes. The PEPTIDEX coupon code provides a verified discount at COA-verified vendors who supply research-grade Epitalon, GHK-Cu, SS-31, and MOTS-c. The code applies at checkout at partner vendors listed on the PEPTIDEX deals page. For longevity peptides specifically, synthesis purity is critical — Epitalon is a tetrapeptide where sequence accuracy and purity (≥99% by HPLC) directly affect the telomerase mechanism. The vendor comparison table on PEPTIDEX filters for COA-verified sources only. → See peptidex.app/peptidex-coupon for current terms and peptidex.app/deals for eligible vendors.